

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872


IN THE CLAIMS:

Please cancel claims 1-24, and add new claims 25-44.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-24. (canceled)

25. (previously presented) A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein:

Ring A is an optionally substituted monocyclic aromatic ring;

R is $-X_1-R^1$;

R^* is $-X_2-R^4$, and R^3 is an optionally substituted aromatic group; or

$-NR^*R^3$, taken together, is an optionally substituted non-aromatic nitrogen containing heterocyclic group;

X is $-C(O)-$ or $-C(R^2)_2-$;

X_1 and X_2 are each independently a bond, S(O), S(O)₂, C(O) or C(O)NH;

R^1 is H or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_1 is a bond, SO or SO₂, then R^1 is not H;

each R^2 is independently H, $-X_4-R^8$ or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

R^4 is H, $-X_6-R^{10}$ or an optionally substituted, aliphatic group, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

provided that when X_2 is a bond, SO or SO₂, then R^4 is not H;

X_4 and X_6 are each independently a straight or branched hydrocarbyl group optionally substituted with one or more groups selected from the group consisting of halo, -OH, =O, C₁-C₃ alkoxy, nitro and cyano;

R^5 and R^6 are each independently H or C₁-C₃ alkyl; and

(Page 2 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

R^8 and R^{10} are each independently H, $-C(O)OR'$ or an optionally substituted, cycloaliphatic group, aromatic group or non-aromatic heterocyclic group;

where,

the optional substituents on the aliphatic group, the cycloaliphatic group or the non-aromatic heterocyclic group are one to three groups each independently selected from the group consisting of halo, R^{11} , $=O$, $=S$, $=NNHR^*$, $=NN(R^*)_2$, $=NNHC(O)R^*$, $=NNHCO_2(alkyl)$, $=NNHSO_2(alkyl)$ and $=NR^*$;

the optional substituents on unsaturated carbon atoms of the aromatic group is R^{11} ;

the optional substituents on a nitrogen atom of the aromatic group or the nitrogen atom of the non-aromatic nitrogen containing heterocyclic group are one to three groups each independently selected from the group consisting of R^+ , $-N(R^+)_2$, $-C(O)R^+$, $-CO_2R^+$, $-C(O)C(O)R^+$, $-C(O)CH_2C(O)R^+$, $-SO_2R^+$, $-SO_2N(R^+)_2$, $-C(=S)N(R^+)_2$, $-C(=NH)-N(R^+)_2$ and $-NR^+SO_2R^+$;

R^{11} is one to four substituents each independently selected from the group consisting of halo, R^0 , $-OH$, $-OR^0$, $-SH$, $-SR^0$, 1,2-methylenedioxy, 1,2-ethylenedioxy, protected $-OH$, phenyl, $[R^{12}]$ -phenyl, $-O(phenyl)$, $-O([R^{12}])$ -phenyl, $-CH_2(phenyl)$, $-CH_2([R^{12}])$ -phenyl, $-CH_2CH_2(phenyl)$, $-CH_2CH_2([R^{12}])$ -phenyl, $-NO_2$, $-CN$, $-N(R')_2$, $-NR'CO_2R^0$, $-NR'C(O)R^0$, $-NR'NR'C(O)R^0$, $-N(R')C(O)N(R')_2$, $-NR'NR'C(O)N(R')_2$, $-NR'NR'CO_2R^0$, $-C(O)C(O)R^0$, $-C(O)CH_2C(O)R^0$, $-CO_2R^0$, $-C(O)R^0$, $-C(O)N(R')_2$, $-OC(O)N(R')_2$, $-S(O)_2R^0$, $-SO_2N(R')_2$, $-S(O)R^0$, $-NR'SO_2N(R')_2$, $-NR'SO_2R^0$, $-C(=S)N(R')_2$, $-(CH_2)_yN(R')_2$, $-C(=NH)-N(R')_2$, $-(CH_2)_yC(O)N(R')_2$, $-(CH_2)_yNHC(O)R^0$ or $-(CH_2)_yNHC(O)CH(V-R')(R')$;

R' is H, R^0 , $-CO_2R^0$, $-SO_2R^0$ or $-C(O)R^0$;

y is 0-6;

V is C_1 - C_6 alkylene;

each R^* is independently H, an aliphatic group or an aliphatic group substituted with R^{12} ;

R^+ is H, phenyl, $[R^{12}]$ -phenyl, $-O(phenyl)$, $-O([R^{12}])$ -phenyl, $-CH_2(phenyl)$, $-CH_2([R^{12}])$ -phenyl, a heteroaryl group, a non-aromatic heterocyclic group, an aliphatic group or an aliphatic group substituted with R^{12} ;

R^0 is an aliphatic group, a cycloaliphatic group, an aromatic group, an aralkyl group or a non-aromatic heterocyclic group, each group being optionally substituted with R^{12} ;

R^{12} is one to four substituents each independently selected from the group consisting of halo, C_1 - C_6 alkyl, (halo) C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, (halo) C_3 - C_8 cycloalkyl, $-CN$, $-CF_3$, $-CHF_2$, $-CH_2F$, $-OCF_3$, $-OCHF_2$, $-OCH_2F$, $-OR'$, $-OR^{13}C(O)R'$, $-C(O)OR'$, $-C(O)N(R^{16})_2$, $-N(R^{16})_2$, $-NO_2$, $-NR^{16}C(O)R'$, $-NR^{16}C(O)OR'$, $-NR^{16}C(O)N(R^{16})_2$, $-NR^{16}SO_2R^{17}$, $-S(O)_qR^{17}$, $-R^{13}NR^{16}C(O)R'$, $-R^{13}C(O)R'$, $-R^{13}NR^{16}C(O)OR'$, tetrazolyl, imidazolyl or oxadiazolyl;

R^{13} is C_1 - C_6 alkyl or C_3 - C_8 cycloalkyl;

(Page 3 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

each R¹⁶ is independently R' or benzyl;

R¹⁷ is R¹³ or -CF₃;

q is 0-2; and

r is 1-3;

provided that the compound is not 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxobutyl)-4-quinolinyl]-butanamide; N-(1-Acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-heptanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxo-3-phenylpropyl)-4-quinolinyl]-benzenepropanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinolinyl]-hexanamide; N-[1,1'-biphenyl]-3-yl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-nitrophenyl)-heptanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(4-methoxyphenyl)-2-methyl-propanamide; N-[1-(4-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-pentanamide; 2-ethyl-N-[1-(2-ethyl-1-oxobutyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-butanamide; N-[1-[(4-fluorophenyl)acetyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinolinyl]-octanamide; N-cyclohexyl-4-[(cyclohexylamino)carbonyl]phenylamino-3,4-dihydro-2-methyl-1(2H)-quinolinecarboxamide; N-[1-(4-ethylbenzoyl)-1,2,3,4-tetrahydro-2,8-dimethyl-4-quinolinyl]-N-(2-methylphenyl)-3-(4-nitrophenyl)-2-propenamide; 3-(4-methoxyphenyl)-N-phenyl-N-[1,2,3,4-tetrahydro-1-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-methyl-4-quinolinyl]-2-propenamide; 4-[(ethoxyoxoacetyl)phenylamino]-3,4-dihydro-2-methyl- γ -oxo-ethyl ester-1(2H)-quinolineacetic acid; N-[1-(3-cyclohexyl-1-oxopropyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-cyclohexanepropanamide; 4-(acetylphenylamino)-3,4-dihydro-2-methyl-gamma-oxo-1(2H)-quinolinepentanoic acid; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-2,2-dimethyl-N-phenyl-propanamide; N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-pentanamide; N-[1-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-propanamide; N-[1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-acetamide; 2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinolinyl]-acetamide; 2-ethyl-N-[1-(2-ethyl-1-oxobutyl)-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl]-N-phenyl-butanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-(3-methoxyphenyl)-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxohexyl)-4-quinolinyl]-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinolinyl)-N-phenyl-2-thiophenecarboxamide; N-[1-(2-fluorobenzoyl)-1,2,3,4-

(Page 4 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

tetrahydro-2-methyl-4-quinoliny]-N-phenyl- hexanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinoliny]- hexanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinoliny]- hexanamide; N-[1-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl- cyclopropanecarboxamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-(4-methylphenyl)- acetamide; 2-methyl-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxopropyl)-4-quinoliny]- propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinoliny]- 2-thiophenecarboxamide; 1-(3,5-dinitrobenzoyl)-N-formyl-1,2,3,4-tetrahydro-2-methyl-N-phenyl-4-quinolinamine; N-[1-(4-chloro-3-nitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl- acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(3-nitrobenzoyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinoliny]- hexanamide; N-[1-(2-furanylcarbonyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-2-furancarboxamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-[3-(4-methoxyphenyl)-1-oxo-2-propenyl]-2-methyl-4-quinoliny]-acetamide; 3-(2-furanyl)-N-[1-[3-(2-furanyl)-1-oxo-2-propenyl]-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-2-propenamide; N-[1-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxo-3-phenylpropyl]-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-octanamide; N-[1-(3-chlorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinoliny]- acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-2-methyl-N-phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-hexanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-heptanamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-2,2-dimethyl-N-phenyl-propanamide; N-[1-(3-fluorobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-acetamide; N-[1-[4-(1,1-dimethylethyl)benzoyl]-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl- acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-2-methyl-N-phenyl-propanamide; 2,2,2-trifluoro-N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(trifluoroacetyl)-4-quinoliny]- acetamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-2,2-dimethyl-N-phenyl-propanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-butanamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-oxoheptyl)-4-quinoliny]-acetamide; Relative stereochemistry N-phenyl-N-[(2R,4S)-1,2,3,4-tetrahydro-2-methyl-1-(1-

(Page 5 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

oxohexyl)-4-quinoliny]-acetamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-pentanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxo-3-phenyl-2-propenyl)-4-quinoliny]-acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-heptanamide; Relative stereochemistry N-[(2R,4S)-1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-acetamide; Relative stereochemistry N-[(2R,4S)-1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-pentanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxopropyl)-4-quinoliny]-propanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-thienylcarbonyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinoliny]-2-furancarboxamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(4-methoxybenzoyl)-2-methyl-4-quinoliny]-acetamide; N-[1-(3,5-dinitrobenzoyl)-1,2,3,4-tetrahydro-2-methyl-4-quinoliny]-N-phenyl-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(4-nitrobenzoyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(2-iodobenzoyl)-2-methyl-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(2-methyl-1-oxopropyl)-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-[(4-methylphenyl)sulfonyl]-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-[(4-nitrophenyl)methyl]-4-quinoliny]-acetamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-methoxybenzoyl)-2-methyl-4-quinoliny]-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-2-methyl-1-(1-oxobutyl)-4-quinoliny]-acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-hexanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-pentanamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-propanamide; 1-benzoyl-1,2,3,4-tetrahydro-4-(N-phenylacetamido)quinaldine; N-(1-acetyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-acetamide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-6-nitro-4-quinolyl)-acetanilide; N-(1-acetyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinolyl)-acetanilide; N-(1-acetyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-acetamide; N-(1-benzoyl-6-bromo-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-acetamide; N-(1-benzoyl-6-chloro-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-acetamide; N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-butanamide; N-phenyl-N-[1,2,3,4-tetrahydro-1-(3-fluorobenzoyl)-2-methyl-4-quinoliny]-hexanamide; N-[1-(3-chloro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; N-[1-(4-fluoro-benzoyl)-2-methyl-6-nitro-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; pentanoic acid (1-benzoyl-6-bromo-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-phenyl-amide; N-(1-benzoyl-6-chloro-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide; N-[6-chloro-1-(4-fluoro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-

(Page 6 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

acetamide; N-[6-bromo-1-(4-fluoro-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-N-phenyl-acetamide; N-(1-benzoyl-6-nitro-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-acetamide; N-(1-benzoyl-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl)-N-phenyl-butyramide; or N-[1-(3-methoxy-benzoyl)-2-methyl-1,2,3,4-tetrahydro-quinolin-4-yl]-2,2-dimethyl-N-phenyl-propionamide.

26. (previously presented) The compound of Claim 25 wherein:


X is $-\text{CHR}^2-$;

R^2 is H, methyl or ethyl;

R^3 is an optionally substituted aromatic group; and

R^5 and R^6 are each H.

27. (previously presented) The compound of Claim 26 wherein the compound is represented by the following structural formula:



28. (previously presented) The compound of Claim 27 wherein R^1 is optionally substituted phenyl.
29. (previously presented) The compound of claim 27, wherein R^4 is methyl, ethyl, propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, $-\text{CH}_2\text{OCH}_3$ or $-\text{CH}_2\text{OCH}_2\text{CH}_3$.
30. (previously presented) The compound of claim 29 wherein:
 R^3 is $[\text{R}^{11}]$ -phenyl, where R^{11} is Br, Cl, $-\text{CH}_3$, $-\text{N}(\text{R}')_2$, $-\text{NHC}(\text{O})\text{OR}'$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{S}(\text{O})_2\text{N}(\text{R}')_2$ or $-(\text{CH}_2)_y\text{C}(\text{O})\text{N}(\text{R}')_2$; and
 R^4 is methyl, ethyl or $-\text{CH}_2\text{OCH}_3$.
31. (previously presented) The compound of Claim 30 wherein R^{11} is one substituent at the para position.

Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872

32. (previously presented) The compound of Claim 27 wherein:
R¹ is H or an optionally substituted, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;
R³ is phenyl or [R¹¹]-phenyl;
R⁴ is H, -CH₂C(O)R¹⁴, -CH₂R¹⁵, -CH₂OR¹⁴ or an optionally substituted, C₁-C₃ alkyl group, cycloalkyl group, aromatic group or non-aromatic heterocyclic group;
R¹⁴ is H or an optionally substituted, alkyl group, aromatic group, cycloalkyl group or non-aromatic heterocyclic group; and
R¹⁵ is an optionally substituted, aromatic group, cycloalkyl group or non-aromatic heterocyclic group.
33. (previously presented) The compound of Claim 27 wherein:
Ring A is phenyl or [R¹¹]-phenyl, where R¹¹ is at the five, six, seven and/or eight position;
R¹ is R¹⁸;
R⁴ is R¹⁸, C₁-C₄ alkyl, -CH₂OH, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂CH₂OCH₃ or -CH₂CH₂OCH₂CH₃; and
R¹⁸ is an optionally substituted, phenyl, pyridyl, furanyl, thiophenyl, isoxazolyl, imidazolyl, pyrazolyl, pyrrolyl, benzofuranyl, tetrazolyl, thiazolyl, benzyl, benzothiazolyl, benzoimidazolyl, benzotriazolyl, benzomorpholinyl, benzopyrazolyl, indolyl, -CH₂-(N-pyridyl), -CH₂-furanyl, -CH₂-thiophenyl, -CH₂-isoxazolyl, -CH₂-imidazolyl, -CH₂-pyrazolyl, -CH₂-pyrrolyl, -CH₂-benzofuranyl, -CH₂-tetrazolyl, -CH₂-thiazolyl, -CH₂-tetrazolyl, -CH₂-benzothiazolyl, -CH₂-benzimidazolyl, -CH₂-O-phenyl, -CH₂C(O)-phenyl, naphthalimidyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or cyclopropyl group.
34. (previously presented) The compound of Claim 33 wherein:
Ring A is phenyl or [R¹¹]-phenyl, where R¹¹ is at the six and/or seven position;
R¹ is phenyl, thiophenyl, furanyl, pyridyl, pyrimidinyl, oxazolyl, isoxazolyl, benzotriazolyl or benzomorpholinyl, each group being optionally substituted with R¹¹;
R³ is [R¹¹]-phenyl; and
R⁴ is methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, -CH₂OCH₃ or -CH₂OCH₂CH₃.
35. (previously presented) The compound of Claim 27 wherein:

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

R^1 is thiophenyl, $[R^{11}]$ -thiophenyl, isoxazolyl, $[R^{11}]$ -isoxazolyl, pyridinyl, $[R^{11}]$ -pyridinyl, benzotriazolyl, $[R^{11}]$ -benzotriazolyl, benzomorpholinyl or $[R^{11}]$ -benzomorpholinyl or R^1 is phenyl or $[R^{11}]$ -phenyl, where R^{11} is halo, $-OR^0$, $-N(R')_2$, oxazolyl or



R^3 is $[R^{11}]$ -phenyl, where R^{11} is Br, Cl, $-CH_3$, $-N(R')_2$, $-NHC(O)OR'$, $-S(O)_2CH_3$, $-S(O)_2N(R')_2$ or $-(CH_2)_yC(O)N(R')_2$; and

R^4 is methyl, ethyl or $-CH_2OCH_3$.


36. (previously presented) The compound of Claim 35 wherein R^3 is $[R^{11}]$ -phenyl, where R^{11} is one substituent at the para position.

37. (previously presented) The compound of Claim 25 wherein:

X is $-CHR^2$; and

R^2 and NR^xR^3 are in a *cis* configuration relative to one another.

38. (previously presented) The compound of Claim 37 where the *cis* configuration is 2S,4R or 2R,4S:



39. (canceled)

40. (previously presented) The compound of claim 25 wherein:


X is $-CHR^2$; and

R^2 and NR^xR^3 are in a *cis* configuration relative to one another, wherein the *cis* configuration is

2S,4R:

Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



41. (previously presented) The compound of Claim 40 wherein:
 R is -C(O)R¹, wherein R¹ is optionally substituted phenyl;
 R² is H, methyl, or ethyl;
 R³ is phenyl or [R¹¹]-phenyl;
 R^x is -C(O)R⁴; wherein R⁴ is methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, -CH₂OCH₃ or -CH₂OCH₂CH₃; and
 Ring A is phenyl or [R¹¹]-phenyl, where R¹¹ is at the six and/or seven position.
42. (previously presented) The compound of claim 40 wherein:
 R³ is [R¹¹]-phenyl, where R¹¹ is Br, Cl, -CH₃, -N(R')₂, -NHC(O)OR', -S(O)₂CH₃, -S(O)₂N(R')₂ or -(CH₂)_yC(O)N(R')₂; and
 R⁴ is methyl, ethyl or -CH₂OCH₃.
43. (previously presented) The compound of Claim 42 wherein R¹¹ is one substituent at the para position.
44. (previously presented) A pharmaceutical composition comprising the compound of Claim 25 and a pharmaceutically acceptable diluent, excipient or carrier.
45. (new) The compound of claim 25 which is represented by a structural formula selected from the group consisting of:

Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



(Page 11 of 27)


Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872



Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



(Page 13 of 27)

Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



(Page 14 of 27)

Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



(Page 15 of 27)


Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872



Practitioner's Docket No. MPI02-110P1RNM









U.S.S.N. 10/678,872



(Page 17 of 27)


Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872




Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872




46. (new) A compound which is represented by a structural formula selected from the group consisting of:



(Page 19 of 27)

Practitioner's Docket No. MP102-110P1RNM


U.S.S.N. 10/678,872



(Page 20 of 27)


Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872




Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872



Practitioner's Docket No. MPI02-110P1RNM


U.S.S.N. 10/678,872



(Page 23 of 27)

Practitioner's Docket No. MP102-110P1RNM

U.S.S.N. 10/678,872



Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

RESPONSE

Originally, claims 1-24 were pending in the above-referenced application. Claims 1-24 were previously canceled, and claims 25-44 were previously presented. With this response, claim 39 has been canceled and has been re-presented as new claim 45, and new claim 46 has been added. No new matter has been added with claim 46. Support for the addition can be found throughout the specification and in claim 45. Claims 25-38 and 40-46 are now pending. As stated in the Office Action Response dated December 28, 2005, the subject matter of original claims 1-7 and 20-24, now canceled, will be pursued in a continuation application.

Rejection under 35 U.S.C. 112, second paragraph:

The Examiner has rejected claim 39 under 35 U.S.C. §112, second paragraph, and has stated that claim 39 is ambiguous since the structures given in the claim are so small that the actual identity of the compound being claimed is unclear. In response to the Examiner's rejection, Applicants have canceled claim 39 and have re-presented the subject matter of this claim as new claim 45 so that the size of the structures being claimed is large enough that the bonds and atoms are clearly evident. Applicants thus respectfully request that the Examiner withdraw the rejection.

Rejection under 35 U.S.C. § 103(a)

The Examiner has rejected claims 25-38 and 40-44 under 35 U.S.C. § 103(a) and has stated that the subject matter of the rejected claims are obvious over Zalukajevs (CA 48:56687, CA 62:22149, CA 59:54789, CA 67:53250, and CA 65:15179e-g) and Funabashi (CA 72:31075). The Examiner has stated that the difference between the compounds taught by Zalukajevs and Funabashi and the instantly claimed compounds is that the compounds of Zalukajevs and Funabashi are hydrogen analogues of the instantly claimed compounds. The Examiner has additionally stated that it would have been obvious to one of ordinary skill in the art to make a hydrogen analog compound of the compounds taught by Zalukajevs and Funabashi with the reasonable expectation of getting compounds having activity against allergic diseases/conditions, and has stated that the rationale is that Zalukajevs and Funabashi all teach the desirability of the compounds and the ability to make a hydrogen analog of a known compound having known utility is well within the skill of the ordinary artisan.

Applicants respectfully submit that that the Examiner has not established a *prima facie* case of obviousness and thus claims 25-38 and 40-44 are not obvious over Zalukajevs (CA 48:56687, CA 62:22149, CA 59:54789, CA 67:53250, and CA 65:15179e-g) and Funabashi (CA 72:31075).

As stated in MPEP § 2142, in order to establish a *prima facie* case of obviousness: 1) there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available in the art, to modify the reference or to combine the teachings; 2) there must be a reasonable

(Page 25 of 27)

Practitioner's Docket No. MPI02-110P1RNM

U.S.S.N. 10/678,872

expectation of success; and 3) the prior art reference (or references when combined) must teach or suggest all of the claim limitations. The teaching or suggestion to make the claimed combination and the reasonable expectation of success *must both be found in the prior art, and not based on applicant's disclosure*. MPEP §2142 also states that impermissible hindsight must be avoided and the legal conclusion must be reached on the basis of the facts gleaned from the prior art.

Applicants respectfully submit that there is no suggestion or motivation in Zalukajevs (CA 48:56687, CA 62:22149, CA 59:54789, CA 67:53250, and CA 65:15179e-g) or Funabashi (CA 72:31075), alone or combined, or combined with knowledge generally available in the art, to modify the reference to arrive at the claimed invention. These references disclose the compounds (N-(1-benzoyl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl-acetamide, N-(1-benzoyl-6-Cl-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl acetamide, and N-(1-benzoyl-6-Br-1,2,3,4-tetrahydro-2-methyl-4-quinoliny)-N-phenyl acetamide, and 4-anilino-1-benzoyl-1,2,3,4-tetrahydroquinolidine, which as acknowledged by the Examiner, are excluded from claim 1), and physical properties thereof, but, contrary to what the Examiner suggests, do not disclose or suggest any pharmacological utility for these compounds. Specifically, as stated in MPEP § 2144.09, if the prior art does not teach any specific or significant utility for the disclosed compounds, then the prior art is not sufficient to render structurally similar claims *prima facie* obvious because there is no motivation for one of ordinary skill in the art to make the reference compounds, much less any structurally related compounds (see *In re Stemniski*, 444 F.2d 581, 170 USPQ 343 (CCPA 1971)).

Additionally, Applicants respectfully submit that, at the time the invention was made, the Zalukajevs and Funabashi disclosures provided no reasonable expectation that modification of their compounds would lead to new compounds that are useful for the diseases and disorders described by the Applicants. Specifically, the teachings of Zalukajevs and Funabashi do not provide a sufficient basis for a reasonable expectation of success because they do not disclose or suggest any pharmacological utility for the compounds disclosed. Furthermore, the cited references do not even suggest making structural modifications to provide the pharmacological activity of the present invention. Thus, one of ordinary skill in the art, *at the time the invention was made*, would not have any expectation that the claimed compounds would have any pharmacological activity in view of Zalukajevs and Funabashi.

Finally, Applicants respectfully submit that Zalukajevs and Funabashi (each alone or when combined) do not teach or suggest all of the claim limitations, because 1) they do not disclose or suggest analogues as claimed by the present invention, and 2) they do not disclose a utility for the compounds disclosed by these references and thus do not teach or suggest the desirability of making any analogues of these compounds as claimed by the present invention (which are useful for the treatment of allergic diseases and disorders).

(Page 26 of 27)